IN2014KN02423A - - Google Patents

Info

Publication number
IN2014KN02423A
IN2014KN02423A IN2423KON2014A IN2014KN02423A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A IN 2423KON2014 A IN2423KON2014 A IN 2423KON2014A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A
Authority
IN
India
Prior art keywords
present
compounds
abc
cftr
transporters
Prior art date
Application number
Other languages
English (en)
Inventor
Sara S Hadida Ruah
Peter D J Grootenhuis
Frederick Van Goor
Jinglan Zhou
Brian Bear
Mark T Miller
Jason Mccartney
Mehdi Michel Jamel Numa
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IN2014KN02423A publication Critical patent/IN2014KN02423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
IN2423KON2014 2006-04-07 2007-04-09 IN2014KN02423A (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79045906P 2006-04-07 2006-04-07
PCT/US2007/008975 WO2007117715A2 (en) 2006-04-07 2007-04-09 Modulators of atp-binding cassette transporters

Publications (1)

Publication Number Publication Date
IN2014KN02423A true IN2014KN02423A (el) 2015-05-01

Family

ID=38477342

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2423KON2014 IN2014KN02423A (el) 2006-04-07 2007-04-09

Country Status (22)

Country Link
US (9) US7776905B2 (el)
EP (5) EP3327016B1 (el)
JP (3) JP5420395B2 (el)
CN (2) CN101460489A (el)
AU (1) AU2007235260B2 (el)
BR (1) BRPI0710965B8 (el)
CA (2) CA2648719C (el)
CY (3) CY1116979T1 (el)
DK (3) DK3091011T3 (el)
ES (4) ES2659364T3 (el)
HU (4) HUE027630T2 (el)
IL (1) IL194576A (el)
IN (1) IN2014KN02423A (el)
LT (1) LT3091011T (el)
MX (1) MX2008012945A (el)
NZ (3) NZ571803A (el)
PL (4) PL2674428T3 (el)
PT (3) PT3091011T (el)
RU (1) RU2451018C2 (el)
SI (4) SI2007756T1 (el)
WO (1) WO2007117715A2 (el)
ZA (1) ZA200809290B (el)

Families Citing this family (106)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP2007504255A (ja) 2003-09-06 2007-03-01 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ć€€ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗć€€ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼”ļ½”ļ½ēµåˆć‚«ć‚»ćƒƒćƒˆćƒˆćƒ©ćƒ³ć‚¹ćƒćƒ¼ć‚æćƒ¼ć®čŖæēƀ因子
CN1925854A (zh) * 2003-11-14 2007-03-07 ę²ƒę³°å…‹ę–ÆčÆē‰©č‚”ä»½ęœ‰é™å…¬åø åÆē”Ø作atpļ¼ē»“åˆå¼¹å¤¹č½¬čæč›‹ē™½č°ƒęŽ§å‰‚ēš„噻唑和噁唑
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP4960708B2 (ja) * 2004-01-30 2012-06-27 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼”ļ½”ļ½ēµåˆć‚«ć‚»ćƒƒćƒˆćƒˆćƒ©ćƒ³ć‚¹ćƒćƒ¼ć‚æćƒ¼ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
ME02970B (me) 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
RU2008109031A (ru) 2005-08-11 2009-09-20 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ (Us) ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Ń‹ Š¼ŃƒŠŗŠ¾Š²ŠøсцŠøŠ“Š¾Š·Š½Š¾Š³Š¾ трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Š¾Š³Š¾ рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š° ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø
HUE032640T2 (en) * 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
NZ569327A (en) * 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
DK3091011T3 (en) 2006-04-07 2018-02-26 Vertex Pharma MODULATORS OF ATP BINDING CASSETTE TRANSPORT
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2007351454B2 (en) 2006-11-03 2013-07-18 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2158183A2 (en) * 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
ES2445447T3 (es) 2007-11-16 2014-03-03 Vertex Pharmaceuticals Inc. Moduladores de isoquinolina de transportadores de casete de uniĆ³n a ATP
KR20100101130A (ko) * 2007-12-07 2010-09-16 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ 3-(6-(1-(2,2-ė””ķ”Œė£Øģ˜¤ė”œė²¤ģ”°[ļ½„][1,3]ė””ģ˜„ģ†”-5-ģ¼)ģ‚¬ģ“ķ“ė”œķ”„ė”œķŒģ¹“ė³µģŠ¤ģ•„ėÆøė„)-3-ė©”ķ‹øķ”¼ė¦¬ė”˜-2-ģ¼)ė²¤ģ”°ģ‚°ģ˜ ź³ ģ²“ ķ˜•ķƒœ
MX2010006238A (es) * 2007-12-07 2010-08-11 Vertex Pharma Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
CA2707494C (en) * 2007-12-07 2018-04-24 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2078711A1 (en) * 2007-12-28 2009-07-15 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
NZ602030A (en) * 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
MX2011003249A (es) 2008-09-29 2011-05-19 Vertex Pharma Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
AU2009308284B2 (en) 2008-10-23 2016-02-04 Vertex Pharmaceuticals, Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
UA104876C2 (uk) * 2008-11-06 2014-03-25 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚Ń–ŠŗŠ°Š»Š· Š†Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Šø atф-Š·Š²'яŠ·ŃƒŠ²Š°Š»ŃŒŠ½Šøх ŠŗŠ°ŃŠµŃ‚Š½Šøх трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Ń–Š²
DK2365972T3 (en) * 2008-11-06 2015-01-19 Vertex Pharma Modulators of atp-binding cassette conveyors
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
PL3835297T3 (pl) * 2010-03-25 2023-09-11 Vertex Pharmaceuticals Incorporated Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2579370C2 (ru) 2010-04-07 2016-04-10 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š¢Š²ŠµŃ€Š“ыŠµ фŠ¾Ń€Š¼Ń‹ 3-(2, 2-Š“ŠøфтŠ¾Ń€Š±ŠµŠ½Š·Š¾[d][1, 3] Š“ŠøŠ¾ŠŗсŠ¾Š»-5-ŠøŠ»)цŠøŠŗŠ»Š¾ŠæрŠ¾ŠæŠ°Š½ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š¾)-3-Š¼ŠµŃ‚ŠøŠ»ŠæŠøрŠøŠ“ŠøŠ½-2-ŠøŠ»)Š±ŠµŠ½Š·Š¾Š¹Š½Š¾Š¹ ŠŗŠøсŠ»Š¾Ń‚Ń‹
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rÅ«gÅ”ties farmacinė kompozicija ir jos ÄÆvedimas
EP2560649A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
SG184987A1 (en) * 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
CA2796646A1 (en) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011255237A1 (en) 2010-05-20 2012-11-29 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103153287A (zh) * 2010-08-23 2013-06-12 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø (R)-1-(2ļ¼Œ2-äŗŒę°Ÿč‹Æ并[d][1ļ¼Œ3]é—“äŗŒę°§ę‚ēŽÆꈊēƒÆ-5-åŸŗ)-N-(1-(2ļ¼Œ3-äŗŒē¾ŸåŸŗäø™åŸŗ)-6-갟-2-(1-ē¾ŸåŸŗ-2-ē”²åŸŗäø™-2-åŸŗ)-1H-吲哚-5-åŸŗ)ēŽÆäø™ēƒ·ē”²é…°čƒŗēš„čÆē‰©ē»„合ē‰©åŠå…¶ę–½ē”Ø
CN102133402B (zh) * 2011-03-24 2013-06-12 首都医ē§‘大学附属北äŗ¬åŒä»åŒ»é™¢ å›Šę€§ēŗ¤ē»“化č·Øč†œč½¬åÆ¼č°ƒčŠ‚å› å­ęŠ‘åˆ¶å‰‚åœØåˆ¶å¤‡ę²»ē–—ē³–å°æē—…čÆē‰©äø­ēš„åŗ”ē”Ø
EP2773349A1 (en) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
WO2013070961A1 (en) * 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2013130669A1 (en) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN107674071B (zh) * 2012-05-11 2021-12-31 åŒę­„åˆ¶čÆ公åø 作äøŗéščŠ±č‰²ē“ č°ƒčŠ‚剂ēš„å«ęœ‰å’”å”‘ēš„ē£ŗ酰čƒŗē±»
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN102816104B (zh) * 2012-08-30 2014-05-21 ęµ™ę±Ÿå¤§å­¦ äø€ē§3-ę°°åŸŗ吲哚ē±»åŒ–合ē‰©ēš„åˆęˆę–¹ę³•
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
JP2016509066A (ja) 2013-02-22 2016-03-24 惖ćƒŖć‚¹ćƒˆćƒ«āˆ’ćƒžć‚¤ćƒ¤ćƒ¼ć‚ŗ ć‚¹ć‚Æ悤惖 ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ļ¼¢ļ½’ļ½‰ļ½“ļ½”ļ½ļ½Œāˆ’ļ¼­ļ½™ļ½…ļ½’ļ½“ ļ¼³ļ½‘ļ½•ļ½‰ļ½‚ļ½‚ ļ¼£ļ½ļ½ļ½ļ½ļ½Žļ½™ ć‚¢ćƒ€ćƒ—ć‚æćƒ¼é–¢é€£ć‚­ćƒŠćƒ¼ć‚¼ļ¼‘ļ¼ˆļ½ļ½ļ½‹ļ¼‘ļ¼‰ć®é˜»å®³å‰¤ćØ恗恦恮ļ¼•ļ½ˆāˆ’ć‚Æćƒ­ćƒ”ćƒŽļ¼»ļ¼“ļ¼Œļ¼”āˆ’ļ½ƒļ¼½ćƒ”ćƒŖć‚øćƒ³
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparaĆ§Ć£o de composiƧƵes farmacĆŖuticas para o tratamento de doenƧas mediadas por condutĆ¢ncia transmembrana da fibrose quĆ­stica (cftr)
TWI690521B (zh) 2014-04-07 2020-04-11 ē¾Žå•†åŒę­„č£½č—„å…¬åø 作ē‚ŗéš±čŠ±č‰²ē“ čŖæēÆ€åŠ‘ä¹‹å«ęœ‰å’”å”‘ä¹‹é†Æčƒŗ锞态čƒŗåŸŗē”²é…øé…Æé”žåŠč„²é”ž
CN103922934B (zh) * 2014-04-11 2016-03-30 北äŗ¬ä¹åØę³°å…‹åŒ»čÆꊀęœÆęœ‰é™å…¬åø ę“»ę³¼äŗšē”²åŸŗ化合ē‰©ēš„ēƒ·åŸŗåŒ–ę–¹ę³•
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorĆ³b, w ktĆ³rych pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CN112250627B (zh) 2014-10-06 2024-02-02 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø å›Šę€§ēŗ¤ē»“化č·Øč†œč½¬åÆ¼č°ƒčŠ‚å› å­č°ƒčŠ‚å‰‚
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
SG11201703391VA (en) * 2014-10-31 2017-05-30 Abbvie S ƀ R L Substituted chromanes and method of use
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma EljƔrƔs nagy ƔteresztƵkƩpessƩgƻ tesztelƵ nagy teljesƭtmƩnyƻ folyadƩk-kromatogrƔfia elvƩgzƩsƩre
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
US10174044B2 (en) 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
CN105153105B (zh) * 2015-08-15 2018-01-19 ęµ™ę±Ÿę°ø宁čÆäøšč‚”ä»½ęœ‰é™å…¬åø 1ā€‘(2,2ā€‘äŗŒę°Ÿč‹Æ并[d][1,3]äŗŒę°§ę‚ēŽÆꈊēƒÆā€‘5ā€‘åŸŗ)ēŽÆäø™ēƒ·ē”²é…øēš„åˆęˆę–¹ę³•åŠå…¶äø­é—“体
EP3519401B1 (en) 2016-09-30 2021-09-29 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IL277491B (en) 2016-12-09 2022-08-01 Vertex Pharma Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø 制备吔å’Æēƒ·åŒ–合ē‰©ēš„ę–¹ę³•
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
EP3710444B1 (en) 2017-11-14 2023-04-12 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø ē”Øę–¼ę²»ē™‚å›Šč…«ēŗ–化ē—‡ä¹‹é†«č—„ēµ„合ē‰©
MD3752510T2 (ro) 2018-02-15 2023-06-30 Vertex Pharma Macrociclii ca modulatori ai regulatorului conductanței transmembranare Ć®n fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor Ć®n tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
DK3860998T3 (da) 2018-10-05 2024-03-25 Annapurna Bio Inc Forbindelser og sammensƦtninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet
CN109880090A (zh) * 2019-02-18 2019-06-14 华ē ”(佛山)ēŗ³ē±³ęę–™ęœ‰é™å…¬åø äø€ē§å«ēŸ³å¢ØēƒÆ仄及ē¢³ēŗ³ē±³ē®”ēš„聚酰äŗščƒŗåƼēƒ­ęę–™ć€åƼēƒ­č†œåŠå…¶åˆ¶å¤‡ę–¹ę³•
TW202115092A (zh) 2019-08-14 2021-04-16 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø å›Šč…«ēŗ–ē¶­åŒ–č·Øč†œå‚³å°ŽčŖæēÆ€č›‹ē™½ä¹‹čŖæēƀ劑
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
TW202120517A (zh) 2019-08-14 2021-06-01 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø č£½å‚™cftrčŖæēÆ€åŠ‘ä¹‹ę–¹ę³•
WO2021195993A1 (zh) * 2020-03-31 2021-10-07 华äøŗꊀęœÆęœ‰é™å…¬åø 小åŒŗꐜē“¢ēš„ę–¹ę³•ć€č£…ē½®åŠē³»ē»Ÿ
AU2021329507A1 (en) 2020-08-20 2023-03-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion
CN112851493B (zh) * 2020-11-10 2022-09-06 å°å·žč‡»ęŒšē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§2,4,5-äø‰ę°Ÿč‹Æ乙é…øēš„åˆ¶å¤‡ę–¹ę³•
DE102021207925A1 (de) * 2021-07-23 2023-01-26 Continental Reifen Deutschland Gmbh Verbindung, Verfahren zu deren Herstellung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Ozonschutzmittel und/oder Farbstoff
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
CN115872895A (zh) * 2023-02-22 2023-03-31 北äŗ¬čÆŗē¦¾č‡“ęŗē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø ē”ØäŗŽč”ē”ŸēŸ­é“¾č„‚č‚Ŗé…øę ‡å‡†å“ä½œäøŗå†…ę ‡ēš„é‡ę ‡čÆ•å‰‚åŠå…¶åˆ¶å¤‡ę–¹ę³•ć€åŗ”ē”Ø

Family Cites Families (174)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5328173A (en) 1976-08-06 1978-03-16 Zenyaku Kogyo Kk Novel phenylmethanenitro compound and its preparation
US4138397A (en) 1978-02-27 1979-02-06 Richardson-Merrell Inc. 6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPS61103861A (ja) 1984-10-27 1986-05-22 Nitto Kasei Kk ć‚¢ćƒŖāˆ’ćƒ«ē½®ę›ć‚·ć‚¢ćƒ³é…¢é…øć‚Øć‚¹ćƒ†ćƒ«ć®č£½é€ ę–¹ę³•
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1998047868A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
JP2002504916A (ja) 1997-06-21 2002-02-12 ćƒ­ć‚·ćƒ„ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚²ć‚¼ćƒ«ć‚·ćƒ£ćƒ•ćƒˆ 惟惃惈 ćƒ™ć‚·ćƒ„ćƒ¬ćƒ³ć‚Æćƒ†ćƒ« ćƒćƒ•ćƒ„ćƒ³ć‚° ęŠ—č»¢ē§»åŠć³ęŠ—č…«ē˜ę“»ę€§ć‚’ęœ‰ć™ć‚‹ćƒćƒ«ćƒ“ćƒ„ćƒ¼ćƒ«é…øčŖ˜å°Žä½“
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med forƶget biotilgƦngelighed
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
DE60028791T2 (de) 1999-09-10 2007-05-24 Novo Nordisk A/S Modulatoren der protein tyrosin phosphatase (ptpases)
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CN1179945C (zh) * 2000-03-09 2004-12-15 小野čÆ品巄äøšę Ŗ式会ē¤¾ å²å“šč”ē”Ÿē‰©ć€å…¶åˆ¶å¤‡ę–¹ę³•åŠē”Ø途
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6562989B2 (en) 2000-08-07 2003-05-13 Yale University Catalyst for aromatic Cā€”O, Cā€”N, and Cā€”C bond formation
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1383799A4 (en) 2001-04-10 2008-08-06 Transtech Pharma Inc PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS
DE60234510D1 (de) 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
AU2002307839B2 (en) * 2001-06-28 2006-03-16 Zoetis P Llc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
BR0215212A (pt) 2001-12-21 2004-12-07 Novo Nordisk As Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composiĆ§Ć£o farmacĆŖutica, e, uso de um composto
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 å°é‡Žč–¬å“å·„ę„­ę Ŗ式会ē¤¾ ļ¼£ļ½ƒļ½’ļ¼”ć‚¢ćƒ³ć‚æć‚“ćƒ‹ć‚¹ćƒˆćŠć‚ˆć³ćć®åŒ»č–¬ē”Ø途
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US20060083784A1 (en) 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
JP4977319B2 (ja) 2002-09-30 2012-07-18 悶 ćƒŖćƒ¼ć‚øć‚§ćƒ³ćƒ„ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ åš¢čƒžę€§ē·šē¶­ē—‡č†œć‚³ćƒ³ćƒ€ć‚Æć‚æćƒ³ć‚¹åˆ¶å¾”å› å­č›‹ē™½č³Ŗé˜»å®³č–¬ćŠć‚ˆć³ćć®ä½æē”Øę–¹ę³•
JP2004131393A (ja) 2002-10-08 2004-04-30 Kowa Co ꘓęŗ¶å‡ŗę€§č£½å‰¤
JP4227389B2 (ja) * 2002-10-09 2009-02-18 ęµœę¾ćƒ›ćƒˆćƒ‹ć‚Æć‚¹ę Ŗ式会ē¤¾ ę’®åƒč£…ē½®åŠć³ćć®č£½é€ ę–¹ę³•
WO2004035571A1 (en) * 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
FR2846327B1 (fr) 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
AU2003286757B2 (en) * 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
DE10306941A1 (de) 2003-02-18 2004-08-26 Merck Patent Gmbh Benzofuranoxyethylamine
WO2004080972A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
AU2004226278B2 (en) 2003-04-03 2010-07-29 Merck Patent Gmbh Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor Xa in the treatment of thrombo-embolic diseases
ES2770035T3 (es) 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de Ć”cido 1,2,4-oxadiazol benzoico y su uso para la supresiĆ³n sin sentido y el tratamiento de enfermedades
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
ATE554766T1 (de) 2003-06-27 2012-05-15 Jackson H M Found Military Med Amphiphile pyridinium-verbindungen, herstellungsverfahren und ihre verwendung
MXPA06001738A (es) * 2003-08-15 2006-05-12 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3.
ATE528291T1 (de) * 2003-08-15 2011-10-15 Lundbeck & Co As H Cyclopropylderivate als nk3 rezeptor-antagonisten
JP2007504255A (ja) * 2003-09-06 2007-03-01 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ć€€ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗć€€ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼”ļ½”ļ½ēµåˆć‚«ć‚»ćƒƒćƒˆćƒˆćƒ©ćƒ³ć‚¹ćƒćƒ¼ć‚æćƒ¼ć®čŖæēƀ因子
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005037802A1 (ja) 2003-10-16 2005-04-28 Sankyo Company, Limited ļ¼•ļ¼ć‚¢ćƒŖćƒ¼ćƒ«ćƒ”ćƒŖ惟ć‚øćƒ³čŖ˜å°Žä½“
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
CN1925854A (zh) 2003-11-14 2007-03-07 ę²ƒę³°å…‹ę–ÆčÆē‰©č‚”ä»½ęœ‰é™å…¬åø åÆē”Ø作atpļ¼ē»“åˆå¼¹å¤¹č½¬čæč›‹ē™½č°ƒęŽ§å‰‚ēš„噻唑和噁唑
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP4960708B2 (ja) 2004-01-30 2012-06-27 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼”ļ½”ļ½ēµåˆć‚«ć‚»ćƒƒćƒˆćƒˆćƒ©ćƒ³ć‚¹ćƒćƒ¼ć‚æćƒ¼ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
BRPI0509282A (pt) 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
US20050222271A1 (en) 2004-03-31 2005-10-06 Le Huang Novel amorphous form of memantine hydrochloride
WO2005117514A2 (en) 2004-06-01 2005-12-15 Tm Bioscience Corporation Method of detecting cystic fibrosis associated mutations
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
ME02970B (me) 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US20060000401A1 (en) 2004-07-01 2006-01-05 Massetti Joseph A Mooring line storage device
JP2008505124A (ja) 2004-07-02 2008-02-21 ć‚¢ćƒ‰ćƒćƒ³ć‚·ć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚¹ćƒ¼ćƒ†ć‚£ć‚«ćƒ« ć‚³ćƒ¼ćƒćƒ¬ć‚¤ć‚·ćƒ§ćƒ³ ćƒ‘ćƒ«ć‚¹é€é”ē”Ø錠剤
KR100927563B1 (ko) 2004-08-06 2009-11-23 ģ˜¤ģ“°ź¹Œ ģ„øģ“ģ•¼ź¾ø ź°€ė¶€ģ‹œķ‚¤ź°€ģ“ģƒ¤ ė°©ķ–„ģ”± ķ™”ķ•©ė¬¼
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
EP1812071A2 (en) 2004-10-13 2007-08-01 PTC Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
MX2007010112A (es) 2005-02-25 2007-10-12 Ono Pharmaceutical Co Compuesto indol y uso del mismo.
EP1865949B1 (en) * 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2006227833A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
ES2398934T3 (es) 2005-03-28 2013-03-22 Toyama Chemical Co., Ltd. Proceso de la producciĆ³n de1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)acetidin-ol o sales del mismo
MX2007012206A (es) 2005-04-08 2007-12-05 Ptc Therapeutics Inc Composiciones de 1,2,4-oxadiazol activo por via oral para terapia de supresion de mutacion interruptora.
AU2006251624A1 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
RU2008109031A (ru) 2005-08-11 2009-09-20 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ (Us) ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Ń‹ Š¼ŃƒŠŗŠ¾Š²ŠøсцŠøŠ“Š¾Š·Š½Š¾Š³Š¾ трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Š¾Š³Š¾ рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š° ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø
CN101287732A (zh) 2005-08-11 2008-10-15 ę²ƒę³°å…‹ę–ÆčÆē‰©č‚”ä»½ęœ‰é™å…¬åø å›Šę€§ēŗ¤ē»“化č·Ø膜ē”µåÆ¼č°ƒčŠ‚å‰‚ēš„č°ƒęŽ§å‰‚
SI1926476T1 (sl) 2005-08-29 2013-07-31 Sanofi-Aventis U.S. Llc Amorfne trdne disperzije 7-kloro-N,N,5-trimetil-4-okso-3-fenil-3,5- dihidro-4H-piridazino/4,5-b/indol-1-acetamida
CA2624683A1 (en) * 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7401405B2 (en) * 2005-10-11 2008-07-22 Silverbrook Research Pty Ltd Method of fabricating inkjet nozzles having associated ink priming features
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
EA015754B1 (ru) 2005-12-21 2011-12-30 ŠÆŠ½ŃŃŠµŠ½ Š¤Š°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøŠŗŠ°, Š.Š’. Š¢Ń€ŠøŠ°Š·Š¾Š»Š¾ŠæŠøрŠøŠ“Š°Š·ŠøŠ½Ń‹ Š² ŠŗŠ°Ń‡ŠµŃŃ‚Š²Šµ Š¼Š¾Š“уŠ»ŃŃ‚Š¾Ń€Š¾Š² тŠøрŠ¾Š·ŠøŠ½ŠŗŠøŠ½Š°Š·Ń‹
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
CA2635214A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
NZ569327A (en) * 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
EA018811B1 (ru) 2006-03-20 2013-10-30 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š”ŠæŠ¾ŃŠ¾Š±Ń‹ ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя тŠ²ŠµŃ€Š“Š¾Š¹ Š“ŠøсŠæŠµŃ€ŃŠøŠø Š»ŠµŠŗŠ°Ń€ŃŃ‚Š²ŠµŠ½Š½Š¾Š³Š¾ срŠµŠ“стŠ²Š° Šø тŠ²ŠµŃ€Š“ыŠµ Š“ŠøсŠæŠµŃ€ŃŠøŠø Š»ŠµŠŗŠ°Ń€ŃŃ‚Š²ŠµŠ½Š½Š¾Š³Š¾ срŠµŠ“стŠ²Š°, ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Š½Ń‹Šµ этŠøŠ¼ сŠæŠ¾ŃŠ¾Š±Š¾Š¼
AU2007226983A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
DK3091011T3 (en) * 2006-04-07 2018-02-26 Vertex Pharma MODULATORS OF ATP BINDING CASSETTE TRANSPORT
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2007134279A2 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR101083177B1 (ko) 2006-10-23 2011-11-11 ģ—ģŠ¤ģ§€ģ—‘ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ»¬ģŠ¤, ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ķŠøė¦¬ģ•„ģ”øė”œ-ķ”¼ė¦¬ė‹¤ģ§„ ė‹Øė°±ģ§ˆ ķ‚¤ė‚˜ģ œ ģ”°ģ •ģ œ
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2007351454B2 (en) 2006-11-03 2013-07-18 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008064259A2 (en) 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
WO2008065732A1 (fr) 2006-11-27 2008-06-05 Nippon Polyurethane Industry Co., Ltd. ProcƩdƩ de production d'un mƩlange Ơ base d'isocyanate modifiƩ contenant une liaison allophanate et une liaison isocyanurate
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
HUE025553T2 (en) 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
ES2445442T3 (es) * 2007-09-14 2014-03-03 Vertex Pharmaceuticals Inc. Moduladores del regulador de la conductancia transmembrana de la fibrosis quĆ­stica
AU2008301907B2 (en) * 2007-09-14 2014-02-20 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2445447T3 (es) 2007-11-16 2014-03-03 Vertex Pharmaceuticals Inc. Moduladores de isoquinolina de transportadores de casete de uniĆ³n a ATP
PT2409975E (pt) 2007-11-22 2015-07-27 Zenyaku Kogyo Kk DispersƵes sĆ³lidas compreendendo um corpo amorfo composto por um composto antitumoral heterocĆ­clico
CA2707494C (en) * 2007-12-07 2018-04-24 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
KR20100101130A (ko) * 2007-12-07 2010-09-16 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ 3-(6-(1-(2,2-ė””ķ”Œė£Øģ˜¤ė”œė²¤ģ”°[ļ½„][1,3]ė””ģ˜„ģ†”-5-ģ¼)ģ‚¬ģ“ķ“ė”œķ”„ė”œķŒģ¹“ė³µģŠ¤ģ•„ėÆøė„)-3-ė©”ķ‹øķ”¼ė¦¬ė”˜-2-ģ¼)ė²¤ģ”°ģ‚°ģ˜ ź³ ģ²“ ķ˜•ķƒœ
MX2010006238A (es) * 2007-12-07 2010-08-11 Vertex Pharma Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2231671B1 (en) * 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
NZ602030A (en) * 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
NZ616097A (en) * 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
ES2501565T3 (es) 2008-04-24 2014-10-02 Bristol-Myers Squibb Company Uso de epotilona D en el tratamiento de enfermedades asociadas a Tau incluyendo enfermedad de Alzheimer
JP5575768B2 (ja) 2008-08-13 2014-08-20 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ č–¬å­¦ēš„ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ęŠ•äøŽ
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
MX2011003249A (es) 2008-09-29 2011-05-19 Vertex Pharma Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
NZ592687A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
AU2009308284B2 (en) 2008-10-23 2016-02-04 Vertex Pharmaceuticals, Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110257223A1 (en) * 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
KR20110074916A (ko) 2008-10-23 2011-07-04 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ļ¼®-(4-(7-ģ•„ģžė¹„ģ‹œķ“ė”œļ¼»2.2.1ļ¼½ķ—µķƒ„-7-ģ¼)-2-(ķŠøė¦¬ķ”Œė£Øģ˜¤ė”œė©”ķ‹ø)ķŽ˜ė‹)-4-ģ˜„ģ†Œ-5-(ķŠøė¦¬ķ”Œė£Øģ˜¤ė”œė©”ķ‹ø)-1,4-ė””ķžˆė“œė”œķ€“ė†€ė¦°-3-ģ¹“ė„“ė³µģŠ¤ģ•„ėÆøė“œģ˜ ź³ ģ²“ ķ˜•ķƒœ
DK2365972T3 (en) 2008-11-06 2015-01-19 Vertex Pharma Modulators of atp-binding cassette conveyors
UA104876C2 (uk) 2008-11-06 2014-03-25 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚Ń–ŠŗŠ°Š»Š· Š†Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Šø atф-Š·Š²'яŠ·ŃƒŠ²Š°Š»ŃŒŠ½Šøх ŠŗŠ°ŃŠµŃ‚Š½Šøх трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Ń–Š²
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
RU2518897C2 (ru) 2009-03-20 2014-06-10 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠŸŃ€Š¾ŠøŠ·Š²Š¾Š“Š½Ń‹Šµ 3-ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š°-4-Š¾ŠŗсŠ¾Ń…ŠøŠ½Š¾Š»ŠøŠ½Š°, ŠæŠ¾Š»ŠµŠ·Š½Ń‹Šµ Š² ŠŗŠ°Ń‡ŠµŃŃ‚Š²Šµ Š¼Š¾Š“уŠ»ŃŃ‚Š¾Ń€Š¾Š² рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š° трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Š¾Š¹ ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø ŠŗŠøстŠ¾Š·Š½Š¾Š³Š¾ фŠøŠ±Ń€Š¾Š·Š°
AU2010295461B2 (en) * 2009-09-17 2016-03-03 Vertex Pharmaceuticals Incorporated Process for preparing azabicyclic compounds
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
JP5789611B2 (ja) * 2009-10-23 2015-10-07 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ åš¢čƒžę€§ē·šē¶­ē—‡č†œć‚³ćƒ³ćƒ€ć‚Æć‚æćƒ³ć‚¹åˆ¶å¾”å› å­ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼ć‚’čŖæč£½ć™ć‚‹ćŸć‚ć®ćƒ—ćƒ­ć‚»ć‚¹
BR112012009584A2 (pt) * 2009-10-23 2019-09-24 Vertex Pharma formas sĆ³lidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluorometil)fenil)-4-oxo-5-(trifluorometil)-1,4-di-hidroquinolina-3-carboxamida
CA2792207A1 (en) * 2010-03-19 2011-09-22 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PL3835297T3 (pl) * 2010-03-25 2023-09-11 Vertex Pharmaceuticals Incorporated Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
US8802868B2 (en) * 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2579370C2 (ru) 2010-04-07 2016-04-10 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š¢Š²ŠµŃ€Š“ыŠµ фŠ¾Ń€Š¼Ń‹ 3-(2, 2-Š“ŠøфтŠ¾Ń€Š±ŠµŠ½Š·Š¾[d][1, 3] Š“ŠøŠ¾ŠŗсŠ¾Š»-5-ŠøŠ»)цŠøŠŗŠ»Š¾ŠæрŠ¾ŠæŠ°Š½ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š¾)-3-Š¼ŠµŃ‚ŠøŠ»ŠæŠøрŠøŠ“ŠøŠ½-2-ŠøŠ»)Š±ŠµŠ½Š·Š¾Š¹Š½Š¾Š¹ ŠŗŠøсŠ»Š¾Ń‚Ń‹
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rÅ«gÅ”ties farmacinė kompozicija ir jos ÄÆvedimas
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CA2796646A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2560649A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2787043B1 (fr) 2010-04-30 2018-03-21 Total Marketing Services Utilisation de dƩrivƩs organogelateurs dans des compositions bitumineuses pour amƩliorer leur rƩsistance aux agressions chimiques
TW201202250A (en) 2010-05-20 2012-01-16 Vertex Pharma Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
AU2011255237A1 (en) 2010-05-20 2012-11-29 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103153287A (zh) * 2010-08-23 2013-06-12 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø (R)-1-(2ļ¼Œ2-äŗŒę°Ÿč‹Æ并[d][1ļ¼Œ3]é—“äŗŒę°§ę‚ēŽÆꈊēƒÆ-5-åŸŗ)-N-(1-(2ļ¼Œ3-äŗŒē¾ŸåŸŗäø™åŸŗ)-6-갟-2-(1-ē¾ŸåŸŗ-2-ē”²åŸŗäø™-2-åŸŗ)-1H-吲哚-5-åŸŗ)ēŽÆäø™ēƒ·ē”²é…°čƒŗēš„čÆē‰©ē»„合ē‰©åŠå…¶ę–½ē”Ø
EP2608775A2 (en) 2010-08-27 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2773349A1 (en) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
WO2013070961A1 (en) * 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
RU2644723C2 (ru) 2012-01-25 2018-02-13 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠŸŃ€ŠµŠæŠ°Ń€Š°Ń‚Ń‹ 3-(6-(1-(2, 2-Š“ŠøфтŠ¾Ń€Š±ŠµŠ½Š·Š¾[d][1, 3]Š“ŠøŠ¾ŠŗсŠ¾Š»-5-ŠøŠ»)цŠøŠŗŠ»Š¾ŠæрŠ¾ŠæŠ°Š½ŠŗŠ°Ń€Š±Š¾ŠŗсŠ°Š¼ŠøŠ“Š¾)-3-Š¼ŠµŃ‚ŠøŠ»ŠæŠøрŠøŠ“ŠøŠ½-2-ŠøŠ»)Š±ŠµŠ½Š·Š¾Š¹Š½Š¾Š¹ ŠŗŠøсŠ»Š¾Ń‚Ń‹
WO2013130669A1 (en) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
IL283276B1 (en) 2012-11-02 2024-01-01 Vertex Pharma Preparations containing 3-(6-(1-(2,2-difluorobenzo[1,3][D]dioxol-5-yl)cycloproponecarboxamide)-3-methylpyridin-2-yl)benzoic acid and N-(5-hydroxy- 2,4-ditert-butyl-phenyl)-4-oxo-H1-quinoline-3-carboxamide and their uses
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
EP3013341A4 (en) 2013-06-26 2017-02-08 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparaĆ§Ć£o de composiƧƵes farmacĆŖuticas para o tratamento de doenƧas mediadas por condutĆ¢ncia transmembrana da fibrose quĆ­stica (cftr)
EP3482748A1 (en) 2013-12-27 2019-05-15 Chugai Seiyaku Kabushiki Kaisha Solid preparations containing tofogliflozin and method for producing the same
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorĆ³b, w ktĆ³rych pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CN112250627B (zh) 2014-10-06 2024-02-02 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø å›Šę€§ēŗ¤ē»“化č·Øč†œč½¬åÆ¼č°ƒčŠ‚å› å­č°ƒčŠ‚å‰‚
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma EljƔrƔs nagy ƔteresztƵkƩpessƩgƻ tesztelƵ nagy teljesƭtmƩnyƻ folyadƩk-kromatogrƔfia elvƩgzƩsƩre
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc ConjuguƩs cystƩamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations

Also Published As

Publication number Publication date
MX2008012945A (es) 2009-01-15
WO2007117715A2 (en) 2007-10-18
HUE026145T2 (en) 2016-05-30
JP2014031384A (ja) 2014-02-20
BRPI0710965B8 (pt) 2021-05-25
CA2869945C (en) 2018-01-23
PL2674428T3 (pl) 2017-01-31
CA2869945A1 (en) 2007-10-18
EP3091011B1 (en) 2017-12-27
PT2674428T (pt) 2016-07-14
IL194576A0 (en) 2009-08-03
US20220411410A1 (en) 2022-12-29
IL194576A (en) 2016-12-29
PL3091011T3 (pl) 2018-06-29
AU2007235260B2 (en) 2013-05-30
US8598181B2 (en) 2013-12-03
EP2007756B1 (en) 2015-08-26
PL3327016T3 (pl) 2021-10-04
US20140057906A1 (en) 2014-02-27
EP3327016A1 (en) 2018-05-30
JP2009533351A (ja) 2009-09-17
US20180162842A1 (en) 2018-06-14
CN103254177A (zh) 2013-08-21
US20240092766A1 (en) 2024-03-21
ES2580803T3 (es) 2016-08-26
US20160332997A1 (en) 2016-11-17
RU2451018C2 (ru) 2012-05-20
ES2882684T3 (es) 2021-12-02
SI3091011T1 (en) 2018-06-29
DK2007756T3 (en) 2015-10-05
HUE036165T2 (hu) 2018-06-28
RU2008144124A (ru) 2010-05-20
NZ611485A (en) 2014-09-26
NZ596889A (en) 2013-06-28
CA2648719C (en) 2015-02-24
SI2674428T1 (sl) 2016-07-29
US20070244159A1 (en) 2007-10-18
ES2554353T3 (es) 2015-12-18
SI3327016T1 (sl) 2021-09-30
HUE027630T2 (en) 2016-10-28
US10975061B2 (en) 2021-04-13
JP5420395B2 (ja) 2014-02-19
CY1120045T1 (el) 2018-12-12
ZA200809290B (en) 2009-10-28
WO2007117715A3 (en) 2008-01-10
US11639347B2 (en) 2023-05-02
US7776905B2 (en) 2010-08-17
CA2648719A1 (en) 2007-10-18
US9758510B2 (en) 2017-09-12
LT3091011T (lt) 2018-04-10
US20150119441A1 (en) 2015-04-30
US20200115366A1 (en) 2020-04-16
EP3091011A1 (en) 2016-11-09
AU2007235260A1 (en) 2007-10-18
CY1116979T1 (el) 2017-04-05
EP2007756A2 (en) 2008-12-31
US20100331344A1 (en) 2010-12-30
EP2674428A1 (en) 2013-12-18
PT3091011T (pt) 2018-03-07
DK3091011T3 (en) 2018-02-26
PL2007756T3 (pl) 2016-01-29
CN101460489A (zh) 2009-06-17
BRPI0710965A2 (pt) 2012-01-31
JP5827297B2 (ja) 2015-12-02
EP3882245A1 (en) 2021-09-22
JP2015120762A (ja) 2015-07-02
HUE055205T2 (hu) 2021-11-29
EP3327016B1 (en) 2021-06-16
SI2007756T1 (sl) 2015-11-30
CY1117731T1 (el) 2017-05-17
NZ571803A (en) 2011-12-22
US10239867B2 (en) 2019-03-26
BRPI0710965B1 (pt) 2020-08-18
ES2659364T3 (es) 2018-03-15
EP2674428B1 (en) 2016-04-06
DK2674428T3 (en) 2016-04-18
US8912199B2 (en) 2014-12-16
PT2007756E (pt) 2015-11-02

Similar Documents

Publication Publication Date Title
IN2014KN02423A (el)
MX357497B (es) Moduladores de transportadores de casete de union a atp.
HK1138586A1 (en) Modulators of cftr cftr
WO2010054138A3 (en) Modulators of atp-binding cassette transporters
HK1140475A1 (en) Azaindole derivatives as cftr modulators
WO2009038913A3 (en) Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
HK1148006A1 (en) Isoquinoline modulators of atp-binding cassette transporters atp
WO2006099256A3 (en) Modulators of atp-binding cassette transporters
NZ583878A (en) Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
AU2010327993A8 (en) 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters
WO2007044560A3 (en) Modulators of atp-binding cassette transporters
MX2014005462A (es) Moduladores de trasportadores de casete enlazante de atp.
MX365890B (es) Moduladores de transportadores con casete de uniĆ³n con atp.
WO2006127588A3 (en) Modulators of atp-binding cassette transporters
WO2009108657A3 (en) Heteroaryl derivatives as cftr modulators
NO20082674L (no) Heterocykliske modulatorer for ATP-bindende kassett-transportere
MX2008002019A (es) Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
DE602004022819D1 (de) Von atp-bindende kassette transportern
WO2005026137A3 (en) Modulators of atp-binding cassette transporters
HK1092353A1 (en) Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
NZ586271A (en) Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
EP2502914A3 (en) Modulators of ATP-binding cassette transporters